atracurium ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
neuromuscular blocking agents with rigid structure 259 64228-79-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • atracurium
  • tracrium
  • atracurium besylate
A non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents.
  • Molecular weight: 929.16
  • Formula: C53H72N2O12
  • CLOGP: 3.30
  • LIPINSKI: 2
  • HAC: 14
  • HDO: 0
  • TPSA: 126.44
  • ALOGS: -7.63
  • ROTB: 26

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 0 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 8.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.65 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 0.10 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 5.70 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.52 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.31 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Nov. 23, 1983 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaphylactic shock 652.75 45.94 157 2363 23476 63463026
Anaphylactic reaction 340.29 45.94 119 2401 65981 63420521
Bronchospasm 191.83 45.94 56 2464 17224 63469278
Hypotension 169.82 45.94 115 2405 272489 63214013
Cardiac arrest 100.78 45.94 56 2464 92489 63394013
Patent ductus arteriosus 61.64 45.94 17 2503 4233 63482269
Pulseless electrical activity 56.15 45.94 18 2502 7503 63478999
Tachycardia 55.04 45.94 42 2478 118114 63368388
Circulatory collapse 53.27 45.94 23 2497 21915 63464587
Stress cardiomyopathy 52.11 45.94 18 2502 9432 63477070
Acute respiratory distress syndrome 51.72 45.94 23 2497 23511 63462991
Wrong product administered 51.24 45.94 16 2504 6125 63480377
Anticholinergic syndrome 51.14 45.94 13 2507 2369 63484133

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaphylactic shock 407.74 45.75 109 2051 15832 34938939
Anaphylactic reaction 153.87 45.75 62 2098 32239 34922532
Bronchospasm 150.16 45.75 46 2114 10685 34944086
Leukocytosis 74.14 45.75 34 2126 24031 34930740
Rash maculo-papular 68.71 45.75 34 2126 28417 34926354
Eosinophilia 68.31 45.75 33 2127 26189 34928582
Hepatic cytolysis 66.02 45.75 27 2133 14469 34940302
Hypotension 61.99 45.75 72 2088 221577 34733194
Trigemino-cardiac reflex 50.67 45.75 9 2151 184 34954587
Erythema 49.29 45.75 42 2118 88738 34866033
Cardiac arrest 46.38 45.75 42 2118 96117 34858654

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaphylactic shock 1008.46 37.92 260 4285 35736 79704107
Anaphylactic reaction 474.27 37.92 178 4367 83565 79656278
Bronchospasm 323.90 37.92 99 4446 24760 79715083
Hypotension 204.44 37.92 181 4364 440136 79299707
Cardiac arrest 126.77 37.92 93 4452 172003 79567840
Circulatory collapse 94.27 37.92 45 4500 37623 79702220
Eosinophilia 89.23 37.92 46 4499 45299 79694544
Tachycardia 77.78 37.92 71 4474 177697 79562146
Stress cardiomyopathy 71.17 37.92 26 4519 11140 79728703
Rash maculo-papular 69.54 37.92 42 4503 56036 79683807
Bradycardia 66.93 37.92 58 4487 135499 79604344
Shock 65.58 37.92 37 4508 43511 79696332
Trigemino-cardiac reflex 61.36 37.92 11 4534 258 79739585
Hepatic cytolysis 60.57 37.92 30 4515 27121 79712722
Leukocytosis 60.29 37.92 35 4510 43420 79696423
Acute respiratory distress syndrome 52.04 37.92 32 4513 44035 79695808
Pulseless electrical activity 51.58 37.92 22 4523 14138 79725705
Wrong product administered 46.57 37.92 18 4527 8994 79730849
Allergy test negative 46.46 37.92 9 4536 325 79739518
Erythema 46.01 37.92 60 4485 223230 79516613
Airway complication of anaesthesia 44.40 37.92 9 4536 411 79739432
Type I hypersensitivity 42.59 37.92 14 4531 4384 79735459
Fatigue 41.65 37.92 3 4542 929724 78810119
Anticholinergic syndrome 41.12 37.92 13 4532 3598 79736245
Anaesthetic complication 39.77 37.92 12 4533 2847 79736996
Procedural hypotension 39.27 37.92 11 4534 2012 79737831
Anaphylactoid shock 38.84 37.92 9 4536 772 79739071
Oxygen saturation decreased 38.66 37.92 42 4503 129005 79610838
Haemodynamic instability 38.15 37.92 19 4526 17363 79722480

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC M03AC04 MUSCULO-SKELETAL SYSTEM
MUSCLE RELAXANTS
MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS
Other quaternary ammonium compounds
CHEBI has role CHEBI:48878 nicotinic antagonists
CHEBI has role CHEBI:51371 muscle relaxants
MeSH PA D018678 Cholinergic Agents
MeSH PA D018680 Cholinergic Antagonists
MeSH PA D009465 Neuromuscular Agents
MeSH PA D009466 Neuromuscular Blocking Agents
MeSH PA D003473 Neuromuscular Nondepolarizing Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018733 Nicotinic Antagonists
MeSH PA D018373 Peripheral Nervous System Agents
FDA EPC N0000175720 Nondepolarizing Neuromuscular Blocker
FDA PE N0000175732 Neuromuscular Nondepolarizing Blockade

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Muscle relaxation, function indication 11977004
General anesthesia indication 50697003
Skeletal Muscle Relaxation for Endotracheal Intubation indication
Hypocalcemia contraindication 5291005
Disorder of lung contraindication 19829001 DOID:850
Hypokalemia contraindication 43339004
Low blood pressure contraindication 45007003
Eaton-Lambert syndrome contraindication 56989000 DOID:0050214
Hypermagnesemia contraindication 66978005
Myasthenia gravis contraindication 91637004 DOID:437
Disorder of electrolytes contraindication 237840007
Hypothermia contraindication 386689009
Malignant hyperthermia contraindication 405501007




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Acetylcholine receptor Ion channel ANTAGONIST IC50 7.77 WOMBAT-PK CHEMBL
Neuronal acetylcholine receptor subunit alpha-2 Ion channel WOMBAT-PK
Neuronal acetylcholine receptor subunit alpha-7 Ion channel ANTAGONIST IC50 8.25 IUPHAR
Neuronal acetylcholine receptor subunit alpha-3 Ion channel ANTAGONIST IC50 9.05 IUPHAR
Neuronal acetylcholine receptor subunit alpha-4 Ion channel ANTAGONIST IC50 8.10 IUPHAR
Small conductance calcium-activated potassium channel protein 3 Ion channel Ki 5.23 CHEMBL

External reference:

IDSource
2GQ1IRY63P UNII
4019619 VUID
N0000147713 NUI
D00758 KEGG_DRUG
64228-81-5 SECONDARY_CAS_RN
1218 RXNORM
C0004234 UMLSCUI
CHEBI:2914 CHEBI
CHEMBL1360 ChEMBL_ID
47319 PUBCHEM_CID
DB13295 DRUGBANK_ID
CHEMBL1200527 ChEMBL_ID
D001279 MESH_DESCRIPTOR_UI
9537 IUPHAR_LIGAND_ID
DB00732 DRUGBANK_ID
1341 MMSL
397 MMSL
4228 MMSL
d00173 MMSL
372835000 SNOMEDCT_US
72752006 SNOMEDCT_US
74074008 SNOMEDCT_US
4018778 VANDF
4019619 VANDF
4734 INN_ID
002409 NDDF
013420 NDDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Atracurium Besylate HUMAN PRESCRIPTION DRUG LABEL 1 0409-1105 INJECTION, SOLUTION 10 mg INTRAVENOUS ANDA 12 sections
Atracurium Besylate HUMAN PRESCRIPTION DRUG LABEL 1 0409-1105 INJECTION, SOLUTION 10 mg INTRAVENOUS ANDA 12 sections
Atracurium Besylate HUMAN PRESCRIPTION DRUG LABEL 1 0409-1109 INJECTION, SOLUTION 10 mg INTRAVENOUS ANDA 12 sections
Atracurium Besylate HUMAN PRESCRIPTION DRUG LABEL 1 0409-1109 INJECTION, SOLUTION 10 mg INTRAVENOUS ANDA 12 sections
Atracurium Besylate HUMAN PRESCRIPTION DRUG LABEL 1 25021-659 INJECTION, SOLUTION 10 mg INTRAVENOUS ANDA 22 sections
Atracurium Besylate HUMAN PRESCRIPTION DRUG LABEL 1 25021-672 INJECTION, SOLUTION 10 mg INTRAVENOUS ANDA 22 sections
Atracurium Besylate Human Prescription Drug Label 1 55150-216 INJECTION, SOLUTION 50 mg INTRAVENOUS ANDA 20 sections
Atracurium Besylate Human Prescription Drug Label 1 55150-216 INJECTION, SOLUTION 50 mg INTRAVENOUS ANDA 20 sections
Atracurium Besylate Human Prescription Drug Label 1 55150-217 INJECTION, SOLUTION 100 mg INTRAVENOUS ANDA 20 sections
Atracurium Besylate HUMAN PRESCRIPTION DRUG LABEL 1 71288-701 INJECTION, SOLUTION 10 mg INTRAVENOUS ANDA 23 sections
Atracurium Besylate HUMAN PRESCRIPTION DRUG LABEL 1 71288-702 INJECTION, SOLUTION 10 mg INTRAVENOUS ANDA 23 sections